Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial.

Autor: Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston., Fang PQ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston., Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Steiner R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.; Now with Department of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Westin J; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Neelapu S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Wang M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Flowers C; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston., Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston., Esmaeli B; Department of Ophthalmic Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Sep 01; Vol. 10 (9), pp. 1195-1203.

Immune Checkpoint Inhibitor Therapy for Periocular Merkel Cell Carcinoma.

Autor: Hohlbein J; Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Ophthalmology, Brooke Army Medical Center, Fort Sam Houston, Texas., Fan J; Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Goldberg H; Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lu T; Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maniakas A; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wong M; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Esmaeli B; Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: besmaeli66@gmail.com.

Publikováno v: Ophthalmology [Ophthalmology] 2024 Aug 08. Date of Electronic Publication: 2024 Aug 08.

Giant Conjunctival and Caruncular Papillomas Causing Functional and Cosmetic Morbidity.

Autor: Fan J; Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A., Goldberg H, Lu T, Esmaeli B

Publikováno v: Ophthalmic plastic and reconstructive surgery [Ophthalmic Plast Reconstr Surg] 2024 Jul 16. Date of Electronic Publication: 2024 Jul 16.

Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Nijhawan N, Ross M, Diba R, Gutstein BF, Ahmadi MA, Esmaeli B. Ophthalmol Plas Recon Surg 2004;20:291–295

Autor: Hans E. Grossniklaus

Publikováno v: American Journal of Ophthalmology. 138:1098-1099

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb14169d6fd7b29d8b477c278f66b908
https://doi.org/10.1016/j.ajo.2004.10.039

Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.

Autor: Cho WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Saade R; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nagarajan P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Aung PP; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Marques-Piubelli ML; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hudgens C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ledesma D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nelson K; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ivan D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zhang M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Torres-Cabala CA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Campbell M; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Alhalabi O; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Prieto VG; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Esmaeli B; Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Curry JL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: Journal of cutaneous pathology [J Cutan Pathol] 2024 May; Vol. 51 (5), pp. 360-367. Date of Electronic Publication: 2024 Jan 10.